Anti-atherogenic effect of berberine on LXRα-ABCA1-dependent cholesterol efflux in macrophages

Journal of Cellular Biochemistry

Volumn 111, Issue 1, 2010, Pages 104-110

  Lee, Tzong Shyuan ^a   Pan, Ching Chian ^a   Peng, Chien Chung ^b,c   Kou, Yu Ru ^a   Chen, Chien Yu ^a   Ching, Li Chieh ^a   Tsai, Tsung Huang ^b,c   Chen, Shu Fen ^c   Lyu, Ping Chiang ^b   Shyue, Song Kun ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

ABCA1; Berberine; Cholesterol efflux; LXR ; Macrophage foam cell

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; BERBERINE; CHOLESTEROL; LIVER X RECEPTOR ALPHA; MESSENGER RNA; NEUTRALIZING ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; FOAM CELL; HUMAN; HUMAN CELL; LIPID STORAGE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BERBERINE; CELL LINE; CHOLESTEROL; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MICE; ORPHAN NUCLEAR RECEPTORS;

EID: 77957147716     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22667     Document Type: Article

References (29)

1. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, Issandou M. 2006. Inhibition of lipid synthesis through activation of AMP kinase: An additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47:1281-1288. (Pubitemid 43830720)
2. Chang TC, Huang CJ, Tam K, Chen SF, Tan KT, Tsai MS, Lin TN, Shyue SK. 2005. Stabilization of hypoxia-inducible factor-1{alpha} by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J Biol Chem 280:36567-36574.
3. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. 2001. A PPAR gamma- LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171.
4. Chen FL, Yang ZH, Liu Y, Li LX, Liang WC, Wang XC, Zhou WB, Yang YH, Hu RM. 2008. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine 33:331-337.
5. Cheng ZF, Zhang YQ, Liu FC. 2009. Berberine against gastrointestinal peptides elevation and mucous secretion in hyperthyroid diarrheic rats. Regul Pept 155:145-149.
6. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58.
7. Cuchel M, Rader DJ. 2006. Macrophage reverse cholesterol transport: Key to the regression of atherosclerosis? Circulation 113:2548-2555.
8. de Winther MP, Hofker MH. 2000. Scavenging new insights into atherogenesis. J Clin Invest 105:1039-1041.
9. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049-1056. (Pubitemid 30217689)
10. Holy EW, Akhmedov A, Luscher TF, Tanner FC. 2009. Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. J Mol Cell Cardiol 46:234-240.
11. Huang C, Zhang Y, Gong Z, Sheng X, Li Z, Zhang W, Qin Y. 2006. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem Biophys Res Commun 348:571-578.
12. Jeong HW, Hsu KC, Lee J-W, Ham M, Huh JY, Shin HJ, Kim WS, Kim JB. 2009. Berberine suppresses pro-inflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296:E995-964.
13. Kalaany NY, Mangelsdorf DJ. 2006. LXRS and FXR: The yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68:159-191.
14. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Li Z, Liu J, Jiang JD. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10:1344-1351.
15. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, Wang YM, Shan N, Zhou ZX, Yang P, You XF, Li ZR, Si SY, Zhao LX, Pan HN, Jiang JD. 2009. Berberine reduces insulin resistance through protein kinase C-dependent upregulation of insulin receptor expression. Metabolism 58:109-119.
16. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277:49982-49988.
17. Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y. 2001. Cardiovascular actions of berberine. Cardiovasc Drug Rev 19:234-244.
18. Lee S, Lim HJ, Park HY, Lee KS, Park JH, Jang Y. 2006. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis 186:29-37.
19. Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. 2007. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 362:853-857. (Pubitemid 47390652)
20. Leng SH, Lu FE, Xu LJ. 2004. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 25:496-502.
21. Li AC, Glass CK. 2002. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8:1235-1242. (Pubitemid 35373554)
22. Li K, Yao W, Zheng X, Liao K. 2009. Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage. Cell Res 19:1006-1017.
23. Lin SJ, Shyue SK, Shih MC, Chu TH, Chen YH, Ku HH, Chen JW, Tam KB, Chen YL. 2007. Superoxide dismutase and catalase inhibit oxidized low-density lipoprotein-induced human aortic smooth muscle cell proliferation: Role of cell-cycle regulation, mitogen-activated protein kinases, and transcription factors. Atherosclerosis 190:124-134.
24. Ohashi R, Mu H, Wang X, Yao Q, Chen C. 2005. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 98:845-856.
25. Rader DJ, Pure E. 2005. Lipoproteins, macrophage function, and atherosclerosis: Beyond the foam cell? Cell Metab 1:223-230.
26. Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W. 1992. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 97:493-497.
27. Shyue S-K, Tsai M-J, Liou J-Y, Willerson JT, Wu KK. 2001. Selective Augmentation of Prostacyclin Production by Combined Prostacyclin Synthase and Cyclooxygenase-1 Gene Transfer. Circulation 103:2090-2095.
28. Wang X, Rader DJ. 2007. Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol 22:368-372. (Pubitemid 46897290)
29. Wang Y, Huang Y, Lam KS, Li Y, Wong WT, Ye H, Lau CW, Vanhoutte PM, Xu A. 2009. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res 82:484-492.